GSK Bio
NEWS
GlaxoSmithKline is lining up a potential new treatment for patients with anemia due to chronic kidney disease following positive results in a Phase III study.
The first week of November was marked by numerous clinical trial announcements. Here’s a look.
GlaxoSmithKline denied reports that they were interested in acquiring Canada’s Aurinia Pharmaceuticals, although some reports claim they are preparing to bid.
Yet another busy week for clinical trial news. Here’s a look.
The life sciences industry continues to be one of the fastest growing industries in the world as the end of the year draws near.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Read about TFF Pharmaceuticals and Augmenta Bioworks’ dry powder COVID-19 antibody formula, the world’s first gene editing clinical trial for PKU, Bayer’s COVID-19 vaccine and other key developments in life sciences research.
GSK shares are climbing in premarket trading on rumors that the company’s consumer health business it intends to spin off into a separate company next year is attracting interest from venture capitalists.
Teamed up with pharma giant GlaxoSmithKline, CureVac is now focusing on a more promising target – second-generation mRNA vaccines.
JOBS
IN THE PRESS